Immune Receptor Expressed on Myeloid Cells 1 (IREM-1) Inhibits B Cell Activation Factor (BAFF)-mediated Inflammatory Regulation of THP-1 Cells Through Modulation of the Activities of Extracellular Regulated Kinase (ERK)

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2010 Jul 22

PMID 20646006

Citations 11

Authors

S-M Lee

Y-P Nam

K Suk

W-H Lee

Affiliations

Soon will be listed here.

Abstract

The immune receptor expressed on myeloid cells 1 (IREM-1) has been known to regulate the activities of myeloid cells through its immunoreceptor tyrosine-based inhibition motifs (ITIMs) in its intracellular region. In order to investigate its effect on macrophage activation, a human macrophage cell line (THP-1) was tested after stimulation of its membrane-bound form of B cell activation factor (BAFF), which has been shown to modulate inflammatory activities through induction of proinflammatory mediator expression and suppression of phagocytosis. IREM-1-specific monoclonal antibodies detected the expression of high levels of IREM-1 in THP-1 cells. Cross-linking of IREM-1 with these antibodies resulted in the blockage of the BAFF-mediated expression of interleukin (IL)-8 and matrix metalloproteinase (MMP)-9 through inhibition of the activation of extracellular regulated kinase (ERK) and phosphorylation/degradation of IκB. Furthermore, cross-linking of IREM-1 also reversed the BAFF-mediated inhibition of phagocytosis. In order to demonstrate the role of ITIM in the IREM-1-mediated suppression of BAFF signalling, a decapeptide containing YADL (an ITIM in IREM-1) was fused with HIV-TAT(48-57) which was required for the internalization of the synthetic polypeptide (TAT-YADL). TAT-YADL, but not control peptides, recapitulated the effect of the anti-IREM-1 monoclonal antibody. These observations indicate that IREM-1 exerted its inhibitory effect on BAFF-medicated signalling through ITIM-mediated regulation of ERK activities in THP-1 cells.

Citing Articles

Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges.

Poggi A, Zocchi M Mol Ther Oncolytics. 2022; 24:26-42.

PMID: 34977340 PMC: 8693432. DOI: 10.1016/j.omto.2021.11.016.

Current Paradigms of Tolerogenic Dendritic Cells and Clinical Implications for Systemic Lupus Erythematosus.

Ritprajak P, Kaewraemruaen C, Hirankarn N Cells. 2019; 8(10).

PMID: 31640263 PMC: 6830089. DOI: 10.3390/cells8101291.

Reverse Signaling of Tumor Necrosis Factor Superfamily Proteins in Macrophages and Microglia: Superfamily Portrait in the Neuroimmune Interface.

Lee W, Seo D, Lim S, Suk K Front Immunol. 2019; 10:262.

PMID: 30838001 PMC: 6389649. DOI: 10.3389/fimmu.2019.00262.

Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression.

Vitalle J, Zenarruzabeitia O, Terren I, Plana M, Guardo A, Leal L Front Immunol. 2017; 8:836.

PMID: 28785262 PMC: 5520290. DOI: 10.3389/fimmu.2017.00836.

SHPS-1 and a synthetic peptide representing its ITIM inhibit the MyD88, but not TRIF, pathway of TLR signaling through activation of SHP and PI3K in THP-1 cells.

Kim E, Suk K, Lee W Inflamm Res. 2013; 62(4):377-86.

PMID: 23314616 DOI: 10.1007/s00011-013-0589-0.

References

Alvarez-Errico D, Aguilar H, Kitzig F, Brckalo T, Sayos J, Lopez-Botet M . IREM-1 is a novel inhibitory receptor expressed by myeloid cells. Eur J Immunol. 2004; 34(12):3690-701. DOI: 10.1002/eji.200425433. View

Christophi G, Hudson C, Panos M, Gruber R, Massa P . Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease. J Virol. 2008; 83(2):522-39. PMC: 2612370. DOI: 10.1128/JVI.01210-08. View

Schneider P . The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol. 2005; 17(3):282-9. DOI: 10.1016/j.coi.2005.04.005. View

Izawa K, Kitaura J, Yamanishi Y, Matsuoka T, Kaitani A, Sugiuchi M . An activating and inhibitory signal from an inhibitory receptor LMIR3/CLM-1: LMIR3 augments lipopolysaccharide response through association with FcRgamma in mast cells. J Immunol. 2009; 183(2):925-36. DOI: 10.4049/jimmunol.0900552. View

Alvarez-Errico D, Sayos J, Lopez-Botet M . The IREM-1 (CD300f) inhibitory receptor associates with the p85alpha subunit of phosphoinositide 3-kinase. J Immunol. 2007; 178(2):808-16. DOI: 10.4049/jimmunol.178.2.808. View

Hardin A, Meals E, Yi T, Knapp K, English B . SHP-1 inhibits LPS-mediated TNF and iNOS production in murine macrophages. Biochem Biophys Res Commun. 2006; 342(2):547-55. DOI: 10.1016/j.bbrc.2006.02.005. View

Mackay F, Schneider P, Rennert P, Browning J . BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2002; 21:231-64. DOI: 10.1146/annurev.immunol.21.120601.141152. View

Xi H, Katschke Jr K, Helmy K, Wark P, Kljavin N, Clark H . Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. J Exp Med. 2009; 207(1):7-16. PMC: 2812551. DOI: 10.1084/jem.20091508. View

Ng L, Mackay C, Mackay F . The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol. 2005; 42(7):763-72. DOI: 10.1016/j.molimm.2004.06.041. View

10.

Bonny C, Oberson A, Negri S, Sauser C, Schorderet D . Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes. 2001; 50(1):77-82. DOI: 10.2337/diabetes.50.1.77. View

11.

Lorenz U . SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev. 2009; 228(1):342-59. PMC: 2669678. DOI: 10.1111/j.1600-065X.2008.00760.x. View

12.

Christophi G, Massa P . Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1. Viral Immunol. 2009; 22(6):371-87. PMC: 2883524. DOI: 10.1089/vim.2009.0052. View

13.

Gorelik L, Gilbride K, Dobles M, Kalled S, Zandman D, Scott M . Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med. 2003; 198(6):937-45. PMC: 2194202. DOI: 10.1084/jem.20030789. View

14.

Lee W, Kim S, Lee Y, Lee B, Kwon B, Song H . Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol. 2001; 21(12):2004-10. DOI: 10.1161/hq1201.098945. View

15.

Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Guzman M . Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Leukemia. 2009; 23(9):1587-97. DOI: 10.1038/leu.2009.99. View

16.

Christophi G, Panos M, Hudson C, Christophi R, Gruber R, Mersich A . Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab Invest. 2009; 89(7):742-59. PMC: 2725397. DOI: 10.1038/labinvest.2009.32. View

17.

Chong Z, Maiese K . The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol. 2007; 22(11):1251-67. PMC: 2515712. DOI: 10.14670/HH-22.1251. View

18.

Nandan D, Tran T, Trinh E, Silverman J, Lopez M . Identification of leishmania fructose-1,6-bisphosphate aldolase as a novel activator of host macrophage Src homology 2 domain containing protein tyrosine phosphatase SHP-1. Biochem Biophys Res Commun. 2007; 364(3):601-7. DOI: 10.1016/j.bbrc.2007.10.065. View

19.

Dillon S, Gross J, Ansell S, Novak A . An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov. 2006; 5(3):235-46. DOI: 10.1038/nrd1982. View

20.

MAY R, Machesky L . Phagocytosis and the actin cytoskeleton. J Cell Sci. 2001; 114(Pt 6):1061-77. DOI: 10.1242/jcs.114.6.1061. View